Presented by Lon Cardon,
Senior Vice President, Target Sciences, GlaxoSmithKline
"In the context of drug discovery, the hope for precision medicine has long been on the horizon"
Despite dramatic advances in annotation of the genetic architecture for common chronic diseases, there has not been the same progress in refined treatments.
Are the common diseases behind simply because of the inherent time lag between target discovery and translation? Or will their inherent multifactorial nature and heterogeneity prove more resistant to refined treatment paradigms?
Lon Cardon discusses some promising approaches and exciting data to address these questions. Fill in the form opposite to hear what he had to say.